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Abstract
Despite advances in the systemic treatment of patients with metastatic melanoma using immune checkpoint and tyrosine
kinase inhibitors (TKI), the majority of stage IV melanoma patients eventually succumb to the disease. We have previously
identified the transcription factor Sox10 as a crucial player in melanoma, yet the underlying molecular mechanisms
mediating Sox10-dependent tumorigenesis remain largely uncharacterized. Here, we show that MEK and RAF inhibitors do
not suppress levels of SOX10 protein in patient-derived cells in vitro, as well as in melanoma patients in vivo. In a search for
pharmacological inhibitors of SOX10, we performed a mass spectrometry-based screen in human melanoma cells.
Subsequent analysis revealed that SOX10 directly interacts with β-catenin, which is a key mediator of canonical Wnt/
β-catenin signaling. We demonstrate that inhibitors of glycogen synthase kinase 3 alpha/beta (GSK3α/β) efficiently abrogate
SOX10 protein in human melanoma cells in vitro and in melanoma mouse models in vivo. The mechanism of action of
GSK3-mediated SOX10 suppression is transcription-independent and relies on the presence of a proteasome degradable
form of β-catenin. Taken together, we provide evidence that activation of canonical Wnt signaling has a profound effect on
melanoma growth and is able to counteract Sox10-dependent melanoma maintenance both in vitro and in vivo.
Introduction
Melanoma is the most aggressive type of skin cancer,
characterized by highly invasive and metastatic features.
Major risk factors are genetic predisposition and exposure
to ultraviolet radiation, and the incidence of melanoma
continues to increase worldwide [1]. While patients with
early stage melanoma can often be cured by surgical
intervention, patients with metastatic disease have a very
poor prognosis. The historically high mortality rate was
largely due to resistance of melanoma to conventional
chemotherapy. Despite recent significant advances in sys-
temic treatment of metastatic melanoma, including targeted
therapies and immune checkpoint inhibitors, which might
even lead to cure in some patients, metastatic melanoma
remains a deadly disease for the majority, since they will
eventually develop resistance to these approaches [2–7]. We
have previously demonstrated that Sox10, a neural crest
transcription factor, plays a crucial role in the development
and maintenance of giant congenital melanocytic nevi and
melanoma [8].
Melanoma originates from cells of the neural crest
(NC) lineage and many parallels have been drawn
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between NC development and melanoma formation.
During embryonic development, WNT signaling is
implicated in neural crest induction and activation of
WNT signaling stimulates the expression of Sox10 and
other NC markers [9–11]. Conversely, blocking WNT
signaling was shown to be associated with the inhibited
expression of NC markers [12].
The canonical WNT pathway is highly controlled by a
complex set of proteins, the so called destruction complex,
to ensure the correct spatial and temporal expression of its
target genes (reviewed in [13]). In the absence of Wnt
ligands, the destruction complex consists among others of
GSK3α/β, which keeps the levels of cytoplasmic β-catenin
low. Once β-catenin is phosphorylated, it is subsequently
ubiquitylated and ultimately degraded in the proteasome.
Upon the binding of secreted Wnts to their cell surface
receptors, β-catenin is no longer phosphorylated and
thereby can escape the proteasome-mediated degradation.
Finally, stabilized β-catenin translocates to the nucleus,
where it associates with co-transcription factors to promote
Wnt target gene transcription [14, 15].
The role of WNT signaling and the β-catenin pathway
has been the subject of intensive research in the field of
melanoma. However, its exact role has remained highly
controversial to date. Canonical WNT signaling has been
implicated in various aspects of melanoma pathogenesis,
including proliferation and invasion [16]. Multiple studies
have reported that elevated levels of β-catenin are associated
with poor survival in patients and the overexpression of a
stabilizing mutation of β-catenin in mice resulted in
increased metastasis [17–20]. In contrast, several other
reports have described that the activation of WNT signaling
is beneficial for melanoma patients [21–24].
In our previous work, we have unambiguously
demonstrated that Sox10 is indispensable for melanoma
initiation and maintenance [8]. In this follow up study, we
set out to identify agents to pharmacologically inhibit
SOX10 protein in melanoma. An unbiased proteomics
screen with the aim to identify proteins interacting with
SOX10 revealed β-catenin as a SOX10 protein partner.
Given the relationship between SOX10 and β-catenin
during neural crest development, we manipulated WNT
signaling in an attempt to regulate SOX10 expression. To
our surprise and in contrast to the interaction in NC
between Sox10 and β-catenin, activation of WNT signal-
ing abolished SOX10 expression and inhibited melanoma
formation. Three independent inhibitors of GSK3α/β
(CHIR99021, LY2090314, and AZD1080) inhibited
SOX10 protein levels in a panel of human melanoma cell
cultures. Moreover, we show that the effect of GSK3α/β
inhibition on SOX10 protein is β-catenin dependent. The
data presented here demonstrate that the canonical WNT
signaling is involved in fine-tuning SOX10 protein levels
in melanoma. Our study is the first to demonstrate the
protein-mediated regulation of the SOX10-WNT axis in
melanoma biology, shedding light on the molecular
mechanism of SOX10 regulation and resolving the con-
troversy around the role of canonical WNT signaling in
melanoma.
Results
Clinically used targeted BRAF or MEK inhibitors do
not interfere with SOX10 expression levels
We have previously shown that SOX10 is expressed in one
hundred percent of primary human melanoma samples and
that its expression is crucial for melanoma initiation, but
also maintenance of established melanomas [8]. Several
studies report that SOX10 expression rate is around
92–97% [25, 26]. Importantly, SOX10 is not only a mel-
anoma marker but is functionally important for melanoma
cells survival. Interestingly, one of the key downstream
targets of SOX10, microphthalmia-associated transcription
factor (MITF) has been previously linked to MAPK
pathway [27]. Taken together, these observations promp-
ted us to investigate the potential effect of current treat-
ments on the expression of SOX10. Given the clinical
observation that the majority of patients treated with small
molecule inhibitors against BRAF or MEK kinases will
eventually relapse (despite impressive initial responses),
we investigated the capacity of those agents to suppress
SOX10 expression in vivo and in vitro [2, 5, 6]. First, we
performed immunohistochemistry for SOX10 in a set of
human melanoma samples. These samples were derived
from the same patients (n= 13) before and after the start of
targeted therapy using a BRAF-inhibitor and MEK-
inhibitor combination therapy (Fig. 1a; one representa-
tive patient is shown). Strikingly, there was no detectable
difference in SOX10 expression after BRAFi treatment
initiation in any of the paired biopsies (Fig. 1a, b). The
efficiency of the treatment is demonstrated by the down-
regulation of pERK expression in the biopsies of the
posttreatment patients (Fig. 1a, c).
Next, we performed western blot analysis in several
early passage melanoma cultures derived from patient
biopsies to analyze effects of MAPK-pathway suppression
on SOX10 expression levels in vitro. We included both
vemurafenib-sensitive and -resistant cultures (Supple-
mentary Fig. S1a, b). SOX10 levels were not changed
upon treatment with the BRAF inhibitors vemurafenib or
dabrafenib, nor with the MEK1 inhibitor selumetinib after
24 h in vitro (Fig. 1d). Strikingly, even the combination of
a BRAF and a MEK inhibitor, which is the new standard
of care treatment in patients with BRAFV600E-mutated
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melanoma, did not alter SOX10 expressions levels
[2, 5, 6]. Taken together, clinically used small molecule
inhibitors of MAPK signaling, which are initially effec-
tive but eventually lead to secondary resistance, do not
influence SOX10 expression levels, neither in vitro nor
in vivo.
β-catenin directly interacts with SOX10, and
pharmacologic activation of WNT signaling
suppresses SOX10 in a β-catenin-dependent manner
Because tyrosine kinase inhibition did not alter SOX10
levels and given the fact that transcription factors are
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Fig. 1 Clinically used targeted BRAF or MEK inhibitors do not
interfere with SOX10 expression levels. a Representative images of
immunohistochemical stainings of human melanoma patient derived
biopsies (n= 13) before (left panel) and after (right panel) combined
BRAF and MEK inhibitor treatment stained for SOX10 (red), pERK
(red) and Pan Melanoma (PanMel), a cocktail of Melanoma antigen
recognized by T cells-1 (MART-1) and Tyrosinase (green). Nuclei
were counterstained with DAPI (blue). b Quantification of SOX10
expression levels pre- and post-BRAF and MEK inhibitor treatment.
c Quantification of pERK expression levels pre- and post-BRAF and
MEK inhibitor treatment. d Representative western blot for the indi-
cated proteins in four different human melanoma cell lines. Levels of
SOX10 expression are not decreased upon treatment with BRAF
inhibitors (vemurafenib and dabrafenib, each 1 μM) or MEK inhibitor
(selumetinib, 1 μM) after 24 h neither in single, nor in double treat-
ments (vemurafenib and selumetinib). In MAPK inhibitor sensitive
cell lines (M98, M00) pERK levels are not detectable anymore, which
indicates the correct function of the drugs, whereas in resistant cell
cultures (M11, M12) pERK levels were not affected (n= 3). In b and
c data represent mean ± s.d. Statistical significance was determined by
paired, two-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001
Western blots shown in d are representative. In each panel, n indicates
the number of independent experiments performed.
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notoriously difficult to target therapeutically, we aimed to
find new protein–protein interaction partners of SOX10 to
identify novel approaches to regulate its function. To this
end, we performed interaction mass spectrometry (MS)
using whole cell extracts (WCE) isolated from the
M010817 primary melanoma culture mixed with recombi-
nant SOX10 protein in different ratios. The mixtures were
cross-linked and analyzed using LC-MS/MS (Fig. 2a) [28].
This highly stringent approach identified β-catenin as a
potential interactor of SOX10 (Supplementary Fig. S2a, b).
To confirm the MS-predicted protein–protein interaction
between SOX10 and β-catenin, we performed a co-
immunoprecipitation (Co-IP) assay (Fig. 2b). We over-
expressed flag-tagged β-catenin and HA-tagged SOX10 in
different ratios in HEK293T/17 cells (which are SOX10-
negative), and analyzed HA-immunoprecipitate for expres-
sion of β-catenin using SDS-PAGE and western blotting.
This approach confirmed the interaction of SOX10 and
β-catenin on the protein level, as indicated by the detected
β-catenin signal in the Co-IP eluates.
In order to interfere only with the signaling function of
β-catenin without compromising cell–cell adhesion, we
inhibited the negative upstream regulator, namely, GSK3α/β,
a component of the β-catenin destruction complex. We used
A
interaction analysis
B
mix in different ratios
proteolysis
cross-linking
LC-MS/MS
cell extract 
melanoma cells
CHIR99021DMSO
D
cnt nssh sh20 sh21 sh77
SOX10
GAPDH
-catenin
CHIR99021
F
SOX10
CHIR99021
M98 M00 M11 M12
-catenin
-actin
- + - + - + - +
- + - + - + - + - +
C
IB: -catenin
92 kDa
IB: SOX10
60 kDa
lys IP      lys IP      lys IP     lys IP
ev 2:1 4:1ev
flag- -cat
HA-SOX10
flag- -cat
HA-SOX10
SOX10 protein
sh- -catenin
-catenin
LY2090314
SOX10
- + - + - + - +
-actin
E
Ph
al
lo
id
in
SO
X1
0
DA
PI
Ph
al
lo
id
in
SO
X1
0
DA
PI
M98 M98
M11 M11
M01 M12 M98 M11
50 m 50 m
50 m 50 m
G
-catenin
SOX10
-actin
cn
t
pc
D
N
A3
-
ca
te
ni
n
S3
3Y
cn
t
pc
DN
A
-
ca
te
n
in
S3
3Y
0.0
0.5
1.0
1.5
2.0
SO
X1
0 
m
RN
A 
(no
rm
a
liz
ed
 to
 
G
AP
DH
)
NS
R. Uka et al.
CHIR99021 (hereafter called either CHIR99021 or CHIR),
a small chemical compound that competes with ATP for the
binding site in GSK3α/β and thereby inhibits GSK3α/β,
leading to the activation of WNT signaling.
As shown in Fig. 2c, immunocytochemical analysis
demonstrated that treatment with CHIR99021 strongly
diminished SOX10 protein expression levels in our panel
of primary melanoma cultures. Vehicle control treated cells
showed a strong nuclear SOX10 expression, whereas 24 h
after CHIR99021 treatment the nuclei were SOX10 nega-
tive (Fig. 2c). The suppression of SOX10 protein expres-
sion was also evident in western blot experiments on WCE
(Fig. 2d). Importantly, this striking effect on SOX10 pro-
tein levels was present in all melanoma cultures, irrespec-
tive of whether they harbor activating BRAF p.V600E,
NRAS p.Q61K, or both mutations, and irrespective of
whether they are sensitive to MAPK inhibition or resistant
(Supplementary Fig. S1a). To exclude off-target effects of
CHIR99021, we made use of two additional GSK3α/β
inhibitors (LY2090314 and AZD1080), which showed
essentially the same effects (Fig. 2e and Supplementary
Fig. S3 and S4).
To test whether SOX10 downregulation is dependent on
the presence of β-catenin, we generated cell cultures stably
expressing control sh (nssh), which represents a real hairpin
but not targeting any human gene and shRNAs targeting the
CTNNB1 gene transcript, which encodes β-catenin. As a
consequence of β-catenin knockdown in M111031 mela-
noma cultures, the suppression of SOX10 protein expres-
sion upon CHIR99021 treatment was fully rescued (Fig. 2f).
We also transfected M111031 melanoma cultures with a
plasmid encoding either wild type β-catenin or a stabilized
mutant p.S33Y that cannot be phosphorylated by GSK3α/β
and thus not degraded by the proteasome. When expressing
β-catenin p.S33Y, there was a clear downregulation of
SOX10 protein (Fig. 2g). This is a further indication that
suppression of SOX10 by CHIR99021 is mediated by
β-catenin stabilization, and is not a direct effect of GSK3α/β
inhibition. Taken together, our findings suggest that
CHIR99021-mediated downregulation of SOX10 is
β-catenin dependent. These findings point to a new
mechanism for the regulation of SOX10 expression via
activation of WNT/β-catenin signaling.
Constitutively active WNT signaling due to
β-catenin stabilizing mutations does not repress
SOX10 expression levels and wild type β-catenin
is predominantly located in the cytoplasm
in melanoma biopsies
All the melanoma cultures from our panel express relatively
low levels of β-catenin and we therefore included two more
cell lines that harbor the stabilizing β-catenin exon 3 p.S37F
mutation, Mel888 and Mel501 (Fig. 3a and Supplementary
Fig. S5) [29]. Strikingly, treatment with CHIR99021 did not
further increase β-catenin levels in mutant cell lines, nor
reduce SOX10 protein levels. This suggests that SOX10 is
regulated by acute changes of β-catenin stability, but not by
continued expression of its constitutively stabilized mutant
forms, which are retained in the nucleus. This is in line with
immunocytochemical experiments, which illustrate that
wild type β-catenin is mostly retained at the cell membrane
in melanoma culture M980513 and translocates to the
nucleus upon stabilization induced by CHIR99021 treat-
ment (Fig. 3b, d). β-catenin p.S37F, however, is strongly
expressed throughout the cytoplasm and the nucleus and
does not change upon GSK3α/β inhibition in Mel888 (Fig.
3c, e). Moreover, CHIR99021 only shows an effect on
SOX10 expression levels when WNT signaling is not
constitutively hyper-activated by β-catenin mutations.
Constitutive activation of canonical WNT signaling (e.g.,
by stabilizing β-catenin exon 3 mutations) has been impli-
cated in different types of cancer. There is an ongoing
debate about the impact of the subcellular localization of
β-catenin on melanomagenesis. It has been shown that the
Fig. 2 β-catenin directly interacts with SOX10, and pharmacolo-
gical activation of Wnt signaling suppresses SOX10 in a β-catenin-
dependent manner. a Schematic representation showing the nLc
Orbitrap mass spectrometry (MS) analysis to identify SOX10-
interacting proteins. M010817 whole cell extract (WCE) was ana-
lyzed performing nLc Orbitrap MS at CovalX. b Interaction of SOX10
and β-catenin was confirmed by co-immunoprecipitation using an anti-
HA antibody for the pull down. c Representative immunocytochemical
stainings indicating the subcellular localization of SOX10 (in red) and
actin cytoskeleton (in green) in the MAPK inhibitor sensitive (M98,
upper panel) and in the resistant human melanoma cell line M11
(lower panel) in presence of DMSO (left panel) or CHIR99021 (for
24 h, 6 μM) (right panel). Inserts show higher magnification of SOX10
immunostainings (n= 3). d A representative western blot of the
indicated proteins in presence or absence of the GSK3 α/β inhibitor
CHIR99021 (for 24 h at 6 μM) in patient-derived melanoma cell cul-
tures sensitive (M98, M00) against targeted MAPK inhibitors or
resistant (M11, M12) (n= 5). e A representative western blot for the
indicated proteins in presence or absence of the GSK3 α/β inhibitor
LY2090314 (for 24 h at 100 nM) in patient-derived melanoma cell
cultures sensitive (M01 and M98) or resistant against MAPK inhibitors
(M12 and M11) (n= 3). f A representative western blot for the indi-
cated proteins of M11 human melanoma cell culture stably expressing
shCTNNB1 constructs cultured in presence or absence of CHIR99021
for 24 h, 6 μM (n= 3). g On the left, representative western blot of the
indicated proteins in the MAPK inhibitor resistant human melanoma
cell culture M11 transiently expressing wild type β-catenin or a sta-
bilizing mutated form of β-catenin (S33Y). Empty pCDNA3 was used
as control (cnt). β-actin was used as loading control. On the right,
SOX10 mRNA expression levels normalized to GAPDH in the MAPK
inhibitor resistant human melanoma cell culture M11 transiently
expressing wild type β-catenin or a stabilized mutated form of
β-catenin (S33Y) (n= 3). Data represent mean ± s.d. In d and e,
β-actin was used as loading control. In f and g, GAPDH was used as
loading control. In each panel, n indicates the number of independent
experiments performed.
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majority of benign nevi are positive for nuclear β-catenin,
whereas melanoma progression is accompanied by the loss
of nuclear β-catenin expression [23, 30–32]. We
complemented those published observations by performing
an analysis of data from The Cancer Genome Atlas (TCGA)
project [33]. Of 469 (31/469 6.61%) melanoma cases
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deposited in the TCGA database, only 6.61% carried a
β-catenin mutation, of which 43.2% were located in exon 3
(Supplementary Fig. S6 and Table 1).
As a read-out for constitutive WNT signaling activation
in patients, we next analyzed whether β-catenin was
retained in the nucleus in a cohort of human melanoma
samples. To this end, we performed immunohistochemical
staining of a tissue micro array (TMA) containing human
samples from primary melanoma (n= 33), metastases (n=
121), and melanoma cultures (n= 66). The samples were
categorized according to SOX10 positivity and the presence
and subcellular localization of β-catenin. As expected and
previously published, all the cores stained positive for
nuclear SOX10 expression (data not shown) [8]. With
respect to β-catenin, we found that a high number of human
samples present low nuclear expression in primary cases
(87.9%), metastases (92.6%), and primary melanoma cul-
tures (98.5%) (Fig. 3f, g).
Taken together, we can conclude that β-catenin is wild
type and expressed in the cytoplasm in the majority of
melanoma biopsies and therefore, the primary melanoma
cultures used in our in vitro experiments represent a reliable
system to analyze the WNT signaling state of melanomas in
patients.
Activation of WNT/β-catenin signaling reduces
invasion and proliferation in melanoma cells in vitro
Melanoma cells depend on SOX10 for survival, and SOX10
haploinsufficiency prevents or even reverts melanoma for-
mation [8]. We therefore assessed next the phenotypic
consequences of reducing SOX10 protein levels by acti-
vating WNT signaling in melanoma cells in vitro. Pro-
liferation was reduced by 100% in long-term proliferation
assays. Importantly, these findings could be reliably con-
firmed using three different GSK3 α/β inhibitors
(CHIR99021, LY2090314, AZD1080) and shSOX10 con-
structs (Fig. 4d, e). Moreover, in MTT assays performed
after 72 h of CHIR99021 treatment, with IC50 values of
3087, 3642, and 2386 nM in M111031, M980513, and
M121224 cells showed an inhibition of proliferation of
100% (Fig. 4b). These observations underline the specific
effect of WNT activation and hence SOX10 depletion in
reducing proliferation of melanoma cultures, rather than an
off target effect of CHIR99021. Of note, CHIR99021 was
equally effective in vemurafenib-sensitive or -resistant
cultures. Moreover, cellular invasion was also significantly
reduced in all the tested primary melanoma cultures after
only 24 h of CHIR99021 treatment (Fig. 4c). Importantly,
the cells were still largely alive after 24 h of CHIR99021
treatment illustrating that the observed reduction in invad-
ing cells is not only a reflection of a greatly reduced
absolute cell number (Fig. 4a).
Several lines of evidence implicate a function of the WNT
pathway in cancer. In particular, mutations in β-catenin
leading to constitutively activated WNT signaling are
observed in different types of cancer, most prominently in
colorectal cancer [23]. Moreover, WNT was identified to be
an oncogene in breast cancer. Therefore, constitutive acti-
vation of WNT signaling is oncogenic in most contexts. To
ensure that CHIR99021 treatment does not constitutively
activate WNT signaling, we analyzed how long β-catenin
expression is elevated upon a pulse of CHIR99021. As early
as 48 h after changing to control medium, we detected a full
recovery to the endogenous β-catenin and SOX10 protein
expression levels in both TKI-sensitive and -resistant mela-
noma cell lines (Supplementary Fig. S7).
Suppression of SOX10 by pharmacologic activation
of WNT signaling is not transcriptional, but
mediated by the proteasome
It was previously shown that Sox10 can act as nuclear-
cytoplasmic shuttle protein [34]. This, together with the fact
Fig. 3 Wild type β-catenin translocates into the nucleus upon
CHIR99021-mediated stabilization in melanoma cell cultures. a A
representative western blot for the indicated proteins of cell lines
carrying a stabilizing mutation in β-catenin (p.S37F) (Mel501,
Mel888). M11 expresses wild type β-catenin and serves as a control.
The human melanoma-derived cell lines were cultured in presence or
absence of CHIR99021 for 24 h, 6 μM (n= 3). b Representative
immunocytochemical stainings indicating the subcellular localization
of β-catenin (in green) in a melanoma patient-derived cell culture
carrying wild type β-catenin (M98) in presence of DMSO (left panel)
or 6 µM CHIR99021 (right panel) for 24 h. Inserts show higher
magnification of immunostainings. c Representative immunocyto-
chemical stainings indicating the subcellular localization of β-catenin
(in green) in a melanoma cell line harboring the stabilizing p.S37F
mutation in β-catenin (Mel888) in presence of DMSO (left panel) or
6 µM CHIR99021 (right panel) for 24 h. Inserts show higher magni-
fication of immunostainings. d β-catenin nuclear localization analysis
of M98 upon DMSO or 24 h of 6 µM CHIR99021 treatment, respec-
tively. e β-catenin nuclear localization analysis of Mel888 upon
DMSO or 24 h of 6 µM CHIR99021 treatment, respectively. f Tissue
Micro Array (TMA) of melanoma cell lines (upper panel) n= 66,
primary melanoma (middle panel) n= 33, or metastases (lower panel)
n= 121, showing the cytoplasmic localization of β-catenin. The
TMAs were analyzed according to the expression level of β-catenin
both nuclear and cytoplasmic. The TMAs were so divided into nuclear
(N) and cytoplasmic (C) localization of β-catenin. The samples were
divided into three groups with expression in <10%, (Cell lines: N=
98.5% C= 9,1%; Primary melanoma: N= 87.9%, C= 6.1%; Metas-
tases: N= 92.6%, C= 8.3%) between 10% and 90% (Cell lines: N=
0%, C= 9,1%; Primary melanoma: N= 9,1% C= 12.1%; Metastases:
N= 7.4% C= 24%) and more than 90% (Cell lines: N= 1.5%, C=
81.8%; Primary melanoma: N= 3.0% C= 81,8%; Metastases: N=
0% C= 67.8%). Asterisks indicate β-catenin negative nuclei, filled
triangles β-catenin positive ones. g The quantification is shown in the
respective analyzed tissues. Data represent mean ± s.d. Statistical sig-
nificance was determined by unpaired, two-tailed Student’s t test. *P <
0.05, **P < 0.01, ***P < 0.001 In each panel, n indicates the number
of independent experiments performed.
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10. . .
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Fig. 4 Activation of Wnt/β-catenin signaling reduces proliferation
and invasion in melanoma cells in vitro. a A representative picture
of the MAPK inhibitor-resistant melanoma patient-derived cell culture
M11 in presence of DMSO (left side) or CHIR99021 (6 µM) for 24 h
(right side) in the upper panel. In the bottom panel a representative
picture of nssh (left side) and shSOX10 (right side) expressing M11
cell culture. b Relative inhibition of proliferation of M98 (sensitive to
MAPK inhibitor), M11, and M12 (resistant) melanoma cell cultures
after treatment with increasing concentrations of CHIR99021 at 72 h.
Drug concentration is indicated in a logarithmic scale (n= 3).
c Relative fold changes in invasion in vitro of MAPK inhibitor
sensitive (M00) and resistant (M11, M12) human melanoma cell
cultures treated with 6 µM CHIR99021 are shown compared with
DMSO (ctrl) (n= 3). d Representative images of colony formation
assay of MAPK inhibitor sensitive cell cultures (M00 and M98) and
resistant cell culture (M11) in presence of 6 µM CHIR99021, 100 nM
LY2090314, 10 µM AZD1080, and shSOX10-expressing, respectively
(n= 3). e Relative quantification of colony formation assay. Data
represent mean ± s.d. Statistical significance was determined by
unpaired, two-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P <
0.001. In each panel, n indicates the number of independent experi-
ments performed.
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that upon activation of Wnt signaling, β-catenin translocates
into the nucleus, raises two hypotheses: (i) since both
SOX10 and β-catenin are transcription factors and thus can
exert their functions partially in the nucleus, the
CHIR99021-mediated regulation of SOX10 occurs in the
nucleus, potentially at a transcriptional level. (ii) Alter-
natively, taking into account that SOX10 is an active shuttle
protein and β-catenin is degraded via the proteasome,
SOX10 degradation might involve the cytoplasmic protea-
some machinery.
To test the first hypothesis, we characterized changes in
SOX10 mRNA levels in the melanoma cultures upon
CHIR99021 treatment. As shown in Fig. 5b, no significant
difference was detected in mRNA levels in CHIR99021
treated cells as compared with controls for up to 12 h after
addition of CHIR99021 to the cells (Fig. 5b and Supple-
mentary Fig. S8a, b). Notably, SOX10 protein levels started
to be downregulated as early as 8 h after addition of
CHIR99021 (Fig. 5a). In line with these findings, an acute
stabilization of β-catenin by transient overexpression of
β-catenin p.S33Y in M111031 showed similar effects.
SOX10 protein levels were suppressed, whereas SOX10
mRNA levels remained unchanged (Fig. 2g). In addition to
SOX10, its downstream target MITF plays a crucial role in
neural crest cells that underwent differentiation into the
melanocyte lineage [15, 35–37]. MITF is known as the
“master transcription regulator” of the melanocyte lineage
inducing expression of a plethora of other genes. Moreover,
it has been reported that Wnt/β-catenin positively regulates
MITF expression [20, 38]. In line with this notion we
sought to determine, whether the effect of CHIR99021 on
SOX10 was mediated via MITF. To this end, we generated
a cell line stably expressing shMITF, in which MITF
knockdown was readily detectable. CHIR99021-mediated
SOX10 downregulation was detected also in absence of
MITF, indicating that the Wnt activation-mediated effect on
SOX10 is independent of MITF (Fig. 5c). Taken together,
these data suggest that CHIR99021-mediated down-
regulation of SOX10 is exerted either at the translational
level or is mediated by a change in SOX10 protein stability.
To assess this further, we next cultured the melanoma cells
in the presence or absence of the proteasome inhibitor
MG132 (Fig. 5d). As expected, proteasome inhibition sta-
bilized β-catenin, since it is rapidly degraded by the pro-
teasome in the absence of WNT signaling (reviewed in
[13]). However, SOX10 was not suppressed as a con-
sequence of this MG132-mediated stabilization, nor by the
combination of MG132 and CHIR99021. In fact, the
CHIR99021-mediated SOX10 suppression was fully res-
cued by proteasomal inhibition. This strongly suggests that
the mechanism of reduction of SOX10 protein levels fol-
lowing pharmacologic, acute β-catenin stabilization is
mediated via proteasomal degradation.
Activation of WNT/β-catenin signaling modulates
the expression of SOX10 transcriptional targets
We investigated transcriptional changes in melanoma cul-
tures upon CHIR99021 treatment. For this purpose, we used
three different melanoma cultures, two of which are sensi-
tive to MAPK inhibitors used in clinical practice (M980513
and M000921), and one derived from a patient cell line that
is intrinsically resistant to vemurafenib (M111031). We
compared the expression changes of SOX10 and Wnt target
genes between cells cultured in the presence or absence of
CHIR99021 for 24 h in triplicates. Efficiency of
CHIR99021 treatment is illustrated in Supplementary Fig-
ure 8. Twenty-four hours after treatment start, we extracted
total RNA and performed a genome wide transcriptional
profiling using RNA sequencing. Hierarchical clustering of
SOX10 and Wnt transcriptional target genes indicates that
treatment with CHIR99021 has a major impact on the
expression of SOX10 target genes (Fig. 5e).
CHIR99021 treatment blocks melanoma growth in
xenografts and significantly increases survival of
genetically engineered melanoma mice
Next, we examined whether the profound effect of
CHIR99021 on melanoma cells in vitro could also be
observed in vivo. To this end, we injected Balb/c nude mice
with a vemurafenib-resistant patient-derived melanoma
culture (M111031). As soon as the first signs of tumor
development were detected, we started to treat the mice
with CHIR99021 (30 mg/kg) or vehicle control (Captisol)
intraperitoneally (i.p.) (n= 6 for both groups) (Fig. 6a). The
mice did not exhibit any signs of treatment-related side
effects, as illustrated by the maintained body weight in both
treated and untreated mice (Supplementary Fig. S9). As
soon as the control group reached the tumor size that was
defined as one of the termination criteria, all the mice were
sacrificed and tumors were dissected. Consistent with our
in vitro data, CHIR99021 efficiently blocked the growth of
tumors in this xenograft model (mean tumor volume
375.7 mm3 in Captisol-treated mice versus 98.1 mm3 in
CHIR99021-treated mice at day 29 post injection, P <
0.0001; Fig. 6b and Supplementary Fig. S10). Immuno-
histochemical analysis of the tumors revealed that
CHIR99021 treatment significantly reduced cell prolifera-
tion as assessed by Ki67 staining. This was accompanied by
increased levels of cleaved caspase-3, indicating an induc-
tion of apoptosis (Fig. 6c, d and Supplementary Fig. S11).
Next, we studied the effects of CHIR99021 in a geneti-
cally engineered mouse model (GEMM) of primary mela-
noma, the Tyr::NrasQ61K Ink4a−/− model. In this model, the
Nras p.Q61K oncogene is expressed under the control of the
tyrosinase promoter. Together with the Ink4a homozygous
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10. . .
knockout, this model develops melanoma with 90% inci-
dence at an age of 6 months [39]. First, we performed a
pharmacodynamic analysis of CHIR99021 treatment. For
this purpose, we injected 30 mg/kg CHIR99021 i.p. daily
and euthanized the mice after 24 or 72 h. Immunohisto-
chemical analysis of the skin revealed a clear reduction of
Sox10 expression after 72 h and β-catenin levels in Sox10
positive cells were increased compared to mice treated with
vehicle control (Fig. 6e, f). Next, we started a long-term
treatment of Tyr::NrasQ61K Ink4a−/− mice that showed the
first signs of tumor development. As in the xenograft
experiment, mice were treated either with 30 mg/kg of
CHIR99021 in Captisol, or with vehicle control (Captisol
15%). Treatment was daily for fourteen days in a row,
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signaling is not transcriptional, but mediated by the proteasome.
a Representative western blots of the indicated proteins in the MAPK
inhibitor resistant human melanoma cell culture M12, at different
timepoints of CHIR99021 (6 μM) treatment (timepoints are shown
directly in the figure). GAPDH was used as loading control (n= 3).
b RNA levels in MAPK inhibitor sensitive (M98) human melanoma
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CHIR99021 (6 µM) treatment are shown compared with DMSO (ctrl)
(n= 3). c Representative western blot of the indicated proteins in the
MAPK inhibitor sensitive human melanoma cell culture (M98). A
representative western blot for the indicated proteins of M98 human
melanoma cell culture stably expressing shSOX10 or shMITF
constructs cultured in presence or absence of CHIR99021 for 24 h,
6 μM. Nssh represents the scrambled shRNA used as control construct
(n= 3). d Representative western blot of the indicated proteins in
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followed by a maintenance treatment of once a week until
reaching termination criteria (Fig. 6g). Captisol-treated mice
rapidly progressed and showed signs of melanoma
development, requiring euthanasia within 1–7 weeks after
treatment start. However, CHIR99021 treatment sig-
nificantly improved median overall survival from 2.3 weeks
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(Captisol) to 9.3 weeks (CHIR99021), after treatment start
(Fig. 6h and Supplementary Fig. S12). Finally, we inves-
tigated whether the effect of CHIR99021 treatment in Tyr::
NrasQ61K Ink4a−/− mice could be validated also in another
GEMM of melanoma.
For this purpose we focused on BrafV600E Pten−/− Tyr::
CreERT2, an inducible genetic melanoma mouse model.
The inducible Cre recombinase under the Tyrosinase pro-
moter is induced by 4-hydroxytamoxifen and drives
expression of the BrafV600E oncogene, the most common
mutation found in human melanoma patients, combined
with a homozygous loss of the tumor suppressor gene Pten.
As observed in the Tyr::NrasQ61K Ink4a−/− mouse model,
the overall survival in the BrafV600E Pten−/− Tyr::CreERT2
was also prolonged significantly in the CHIR99021 treated
group compared with the control group (Fig. 6i, j).
Consistent with in vitro data, we demonstrate that tem-
poral pharmacologic activation of WNT/β-catenin signaling
by treatment with the GSK3α/β inhibitor CHIR99021
markedly decreases melanoma tumor growth by inhibiting
proliferation and inducing apoptosis also in GEMM of
melanoma (Fig. 7).
Discussion
Although recent great improvements in therapies against
metastatic melanoma have been achieved using targeted
inhibitors against the MAPK signaling pathway or immune
checkpoints, primary and secondary resistance against those
approaches still pose a major clinical problem. By far, most
patients suffering from metastatic melanoma will eventually
succumb to their disease [1]. Finding new therapies that
improve the survival of malignant melanoma patients is
therefore still a highly unmet medical need. β-catenin is
known to be dysregulated in many types of cancers,
including melanoma [40]. Although β-catenin mutations
have been detected in 23% of melanoma cell lines [29], this
is a rare event in primary, uncultured melanomas (about
5%) [41–44]. The impact of this deregulation and the
functional implications are very controversial and have not
been fully clarified. Increased levels of β-catenin have been
associated with a better outcome for melanoma patients
[23]; whereas other publications found that the loss of
Fig. 6 CHIR99021 treatment blocks tumor growth in xenografts
and improves overall survival of genetic melanoma mouse models.
a Experimental scheme of injection of the MAPK inhibitor resistant
human melanoma cell culture M11 into both flanks of immunocom-
promised mice. Subsequent i.p. treatment with vehicle (Captisol) or
CHIR99021 (n= 4/treatment group). b Tumor growth kinetics with
(n= 4) and without (n= 4) CHIR99021 treatment in xenografts
established from the MAPK inhibitor resistant human melanoma cell
culture M11. c Representative histologic analysis (n= 8) of H&E,
Ki67 and Cleaved Caspase 3 stainings of patient-derived xenografts
treated with vehicle (Captisol) (top) or CHIR99021 (bottom).
d Quantification of stainings of proliferative (top) and apoptotic cells
(bottom) in M11-derived xenografts treated with either vehicle (Cap-
tisol) or CHIR99021. e Representative immunostaining of Sox10 (red)
and β-catenin (green) of skin of 5-month-old mice from the Tyr::
NrasQ61KINK4a−/− melanoma mouse model treated with vehicle
(Captisol) (left panel) or CHIR99021 (right panel) daily for 3 days in a
row. Inserts show higher magnification of Sox10 and β-catenin
immunostaining. f Quantification of subcellular localization of
β-catenin of mice skin treated with either Captisol (vehicle) or
CHIR99021 for 24 or 72 h (once every 24 h, 30 mg/kg). g Experi-
mental scheme of treatment of 4–5-month-old-mice from the Tyr::
NrasQ61KINK4a−/− melanoma mouse model with either vehicle
(Captisol) or CHIR99021 (30 mg/kg) (n= 8/treatment group).
h Kaplan–Meier survival analysis of vehicle (Captisol) treated mice
compared to CHIR99021 treated mice (n= 8/treatment group) from
the Tyr::NrasQ61KINK4a−/− melanoma mouse model. i Representative
picture of two BrafV600E Pten−/− Tyr::CreERT2 mice (6–10 weeks old)
treated with vehicle (Captisol) (left) or with 30 mg/kg CHIR99021
(right) sacrificed at the same time. j Kaplan–Meier survival analysis of
vehicle (Captisol) treated mice compared to CHIR99021 treated mice
(n= 3/treatment group) from the BrafV600E Pten−/− Tyr::CreERT2
melanoma mouse model. Data in b represent mean tumor volume ±
s.e.m. Statistical significance was determined by log-rank
(Mantel–Cox) test (h, j) or two-tailed Student’s t test (b, d, f).
*P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 7 A schematic illustration of the effect of CHIR99021 on the
level of SOX10 protein. CHIR99021 is a small chemical compound
that competes with ATP for the binding site in GSK3α/β kinase and
thereby inhibits GSK3α/β, leading to the activation of WNT signaling.
SOX10 protein levels are reduced following pharmacologic, acute
β-catenin stabilization, and this is mediated via proteasomal
degradation.
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β-catenin counteracts melanoma formation [17]. This shows
that WNT/β-catenin signaling has a profound, context-
dependent impact on melanoma formation. In order to
analyze these contradictory assertions, we further investi-
gated the role of canonical WNT signaling in SOX10 reg-
ulation in melanoma.
SOX10 is a transcription factor that is crucial in neural
crest development and we have recently identified it as a
novel promising candidate for melanoma treatment [12].
Interestingly, the targeted inhibitors of the MAPK sig-
naling pathway, which are successfully being used in
clinical routine, did not alter SOX10 levels in primary
melanoma cultures in vitro, nor in vivo in human patient
samples, suggesting that maintaining SOX10 levels might
be a mechanism of later, acquired resistance. However, we
have now identified a new mechanism to successfully
suppress SOX10 pharmacologically in malignant mela-
noma. We have established a connection between SOX10
and the WNT/β-catenin signaling pathway by identifying
β-catenin as a direct protein-protein interaction partner of
SOX10 in an unbiased MS-based approach in melanoma.
This interaction has functional consequences, since in
contrast to the situation in neural crest development where
activation of WNT signaling results in expression of
SOX10 [12], activation of WNT signaling by inhibiting
the negative regulator GSK3α/β pharmacologically using
different compounds potently suppresses SOX10 in pri-
mary melanoma cultures. This reduces cell survival and
invasion in vitro, as well as tumor formation in vivo.
Suppression of SOX10 expression occurs at the protein,
not at the mRNA level, and it is mediated by the protea-
some, since proteasome inhibition rescues SOX10
expression. Importantly, the suppressive effect on SOX10
is β-catenin dependent, as shown by shRNA-mediated
rescue experiments. Moreover, RNA-sequencing findings
showed a large overlap in transcriptomic changes between
shRNA-mediated SOX10 suppression and suppression
induced by treatment with a GSK3α/β inhibitor. This
observation further confirms a specific effect induced by
WNT/β-catenin signaling, rather than an off-target effect
mediated by other GSK3α/β substrates. Intriguingly, a
study by Zhou et al. demonstrated that SOX10 acts as an
oncogene and interacts with WNT/β-catenin signaling in
hepatocellular carcinoma [45].
The role of WNT/β-catenin signaling in melanoma
initiation and progression is very controversial despite
extensive in vitro studies, in vivo modeling, and patient
cohort studies. On the one hand and in line with our
observations, there are several studies suggesting that acti-
vation of WNT/β-catenin might be a potential therapeutic
strategy. It was shown to reduce melanoma cell proliferation
in vitro by inducing genes involved in melanocyte differ-
entiation and in line with that, nuclear β-catenin expression
was lost during melanoma progression in patient samples
[23]. In another study, pharmacologic inhibition of GSK3α/
β was shown to reduce proliferation of melanoma cells and
in vivo growth in a xenograft experiment [21]. Third, in a
chemical-genetic screen riluzole was found to activate
WNT/β-catenin signaling in melanoma cells, to promote
pigmentation and to decrease proliferation [46]. And lastly,
secreted WNT5A (as opposed to WNT3A) has been shown
to negatively regulate WNT/β-catenin signaling in several
cancer types, including in a subgroup of melanoma patients
exhibiting acquired resistance to BRAF-inhibition [19].
Reducing WNT5A by siRNA in this model activated
canonical WNT signaling and provoked cell death, coun-
teracting melanoma formation. However, none of those
studies related activation of WNT/β-catenin to suppression
of SOX10 protein levels and connected this event to the
observed phenotypic changes.
On the other hand, some studies presented apparently
contrary results and made observations that activation of
WNT/β-catenin promotes melanomagenesis and metastatic
spread. Damsky et al. utilized the BrafV600E/Pten−/−
GEMM to study the effect of β-catenin alterations on
melanoma initiation and metastasis [17]. β-catenin knock
out abrogated formation of melanoma in this model,
whereas introduction of an exon 3-deleted, pathologically
stabilized β-catenin mutant mimicking constitutively acti-
vated WNT signaling increased metastasis formation.
Sox10 expression was assessed at the mRNA level only in
these mouse models, and no differences were observed, in
line with our observations that this regulation happens at
the protein level. However, this mouse model represents
only a minority of melanoma patients, since exon-3
mutations are exceedingly rare in primary and metastatic
cutaneous or uveal melanomas, as has been published and
as shown by our analysis of the TCGA database
[42, 47, 48]. No conclusions can be drawn from those
observations with respect to the potential therapeutic ben-
efit of activating WNT/β-catenin signaling in melanomas
with wild-type β-catenin. Indeed, we have also observed
that inhibiting GSK3α/β in melanoma cell lines carrying a
classical exon-3 mutation (β-catenin p.S37F [29]) in the
GSK3α/β consensus site did not have any effect on SOX10
protein levels. Presumably, because the cells have bypassed
the SOX10 suppressing effect of activated WNT/β-catenin
signaling and adapted to the constantly elevated signaling
levels in order to maintain SOX10. From those findings,
one might also conclude that the small subset of melanoma
patients harboring a stabilizing exon-3 mutation may not
derive benefit from treatment with GSK3α/β inhibitors.
Another study showed that WNT5A can exert a dichot-
omous role in melanoma [49]. On the one hand it signals
through the ROR2/Fzd2/5 receptor complex to degrade
β-catenin, on the other hand it can also signal through the
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LRP6/Fzd4 receptor complex to stabilize β-catenin via
ARF6. Interestingly, both mechanisms appeared to increase
invasion. However, experimental proof that the latter
mechanism is functionally dependent on β-catenin is lack-
ing and it is therefore also conceivable that WNT5A signals
through ARF6 and unknown intermediates to regulate
invasion independent from β-catenin and that stabilization
of β-catenin in this context is a bystander rather than e
driver effect (reviewed in [18]). Our rescue and the RNA-
sequencing experiments on the other hand demonstrate that
the impairment of melanoma cell survival provoked by
SOX10 suppression upon GSK3α/β inhibition is dependent
on β-catenin, suggesting a direct involvement of canonical
WNT/β-catenin signaling.
Taken together, we have identified a SOX10 suppressing
function of activating WNT/β-catenin signaling pharmaco-
logically, by inhibiting its negative regulator GSK3α/β. This
impacted significantly on survival of melanoma cells.
Importantly, this approach was also efficient in primary
melanoma cultures, which had been established from
patients with an acquired resistance to TKI treatment. Our
findings presented in this work, and a previous study from
the Moon lab [23] suggest that pharmacological activation
of WNT/β-catenin signaling in patients with malignant
melanoma has therapeutic potential and should next be
tested in early phase clinical trials.
Methods
Reagents
CHIR99021 (S1263, Selleckchem, distributed by
LuBioScience, Zurich, Switzerland) was used at different
concentrations. LY2090314 (S7063, Selleckchem) was used
at 100 nM. AZD1080 (S7145, Selleckchem) was used at
10 µM. Vemurafenib (PLX4032, RG7204), (S1267, Sell-
eckchem) was used at 1 μM. Dabrafenib (S2807, Sell-
echchem) was used at 1 μM. Selumetinib (AZD6244),
(S1008, Selleckchem) was used at 1 μM MG-132, (S2619,
Selleckchem) was used at 20 μM.
Cell culture
A panel of different patient-derived melanoma cultures was
obtained from the laboratory of Prof. M. Levesque from
Dermatology, USZ (cf Table 1). Two more cell lines from
the laboratory of L. Sommer, Anatomy, UZH were
obtained; these cell lines harbor a mutation in β-catenin
(pS37F). Cells were cultured in RPMI-1640 medium
(L0998-500, Dominique Dutscher) enriched with 10% FCS
(S181B-500, Dominique Dutscher), L-Glutamine, and Na-
Pyruvat (11360-039, Gibco) (1% each).
Proliferation, invasion, colony formation, and cell
viability assays
Colony formation assay
3000 cells/well were plated in a six-well plate. Medium
was changed every other day until the control was con-
fluent. The cells were subsequently fixed for 10 min in 4%
paraformaldehyde (109444 U-58, Kantonsapotheke
Zürich, Switzerland, 4% in PBS) and stained with 0.5% of
Crystal Violet solution (2500 ml of ethanol 96%, 25 g of
Crystal Violet, 40 g NaCl, 2250 ml water, 250 ml paraf-
ormaldehyde 37%).
Cell viability assay
2000 cells/well were plated in a 96 well plate. After 24 h of
incubation, cells were cultured in triplicates in the presence of
either vemurafenib or CHIR99021 at serial dilution con-
centrations of the drug. After 72 h the medium was removed
and 100 μL of resazurin (R7017, Sigma), 0.5mg/ml was
added for 1–4 h and incubated at 37 °C. The absorbance at
570 nm was measured using a Spark multimode microplate
reader (TECAN, Männedorf, Switzerland).
Invasion assay
Cells were seeded 48 h prior to the assay at 60–80% den-
sity. The cells were starved (3% FCS) for 48 h. Inserts
(354480, Corning Biocoat Matrigel Invasion Chamber for
invasion assay) were placed into 24 well chambers (con-
taining 800 µl of starving medium) and filled with 500 µl
starving medium and left for rehydration for 2 h. The
medium from the insert was removed and between 350 and
500 µl of a 1 × 105 cells/ml cell suspension was added.
800 µl of complete medium was added to the well. The plate
was then incubated for 22 h. The invasion potential of the
cells was examined by staining the remaining cells in the
insert with 1:1000 Hoechst 33342 Tri-Hydrochloride, Tri-
hydrated (H1399, Molecular probes by life technologies)
in PBS.
shRNA lentivirus production and infection
The following shRNAs were used for long-term lentiviral
knockdowns: SOX10 (TRCN0000018984, Sigma-Aldrich),
MITF (TRCN0000329793, Sigma-Aldrich), β-catenin (TRCN
0000314920, The RNA Consortium (TRC Project, Broad
Institute). Nssh: mission shRNA control vector SHC002 – ca
acaagatgaagagcaccaa; sh20: pLKO.1 shCTNNB1_TRCN0000
314920 – gcttggaatgagactgctgat; sh21: pLKO.1 shCTNNB
1_TRCN0000314921 – tctaacctcacttgcaataat; sh77: pLKO.1
shCTNNB1_TRCN0000314977 – gggagtggtttaggctatttg.
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Lentivirus production and subsequent infection of melanoma
cell lines, was performed following Addgenes’ protocol. In
brief, melanoma cultures were plated and infected the fol-
lowing day with virus. After 24 h the virus-containing-
medium was removed, and after 48 h puromycin (sc-
108071A, Santa Cruz) was added (1 µg/ml) to select for the
cells that stably integrated the shRNA.
RNA extraction, reverse transcription, and
quantitative PCR
Whole RNA was isolated and DNAse treated from the
melanoma cultures using the RNeasy Mini Kit (74106,
Qiagen) according to the manufacturers’ protocol.
One microgram RNA was reverse transcribed using
GoScript Reverse Transcriptase (A501C, Promega) and
oligo(dT) 15 Primer (C110A, Promega). Quantitative real
time PCR was performed using the Rotor-Gene SYBR
Green PCR kit (204076, Qiagen) on a Rotor-Gene Q
instrument (SN: R 030962, Qiagen). RNA levels were
normalized to the housekeeping gene GAPDH. The fol-
lowing primers were used: huGAPDH fw 5′ ACCACAGT
CCATGCCATCAC; huGAPDH rv 5′ TCCACCACCCTG
TTGCTGTA; huSOX10 fw 5′ CCTCACAGATCGCCTAC
ACC; huSOX10 rv 5′ CATATAGGAGAAGGCCGAG
TAGA.
RNA sequencing and analysis
For each of the melanoma cultures (M980513, M000921,
and M111031) there were two different conditions, per-
formed in biological triplicates, each: (i) control (DMSO),
(ii) 6 μM CHIR99021 for 24 h. The RNA extracted from the
melanoma cultures was sent to Functional Genomic Center
Zurich for RNA sequencing. Datasets are available under
GEO accession number 146415.
Bioinformatics
The Illumina reads recorded in fastq files, have been pro-
cessed with trimmomatic (v 0.35), then aligned to the
human genome (GRCh38) using Star [50] (v 2.4.2a), then
processed with samtools. The reads for each gene have been
counted using featureCounts (v1.5.0) from the subread
package [51]. The count table has been processed statisti-
cally, looking for differential expression using generalized
linear model approach with edgeR Bioconductor [52]
packages with appropriate contrasts between groups. The
differences between the groups have been studied using
heatmaps (pheatmap) [53]. Annotated WNT and SOX10
transcriptional target gene lists were obtained from Meta-
core (https://portal.genego.com/).
Western blotting
Treated cells were washed and collected in ice-cold PBS.
The proteins were extracted from the cell pellet using TNN
lysis buffer (Tris pH 7.5 50 mM, NaCl 250 mM, EDTA
5 mM, NP-40 0.5%, NaF 50 mM, EGTA 0.5 mM), con-
taining complete ULTRA protease inhibitor
(05892970001, Roche) and PhosSTOP (4906837001,
Roche). After 15 min of incubation on ice, cell lysates
were collected for 13 min at 14,000 rpm at 4 °C. The
protein-containing supernatant was used immediately. We
quantified the extracted proteins by Pierce BCA assay
according to the manufacturers’ instructions (23227,
ThermoFisher Scientific). 30 µg of whole cell protein
lysates were loaded on precast Tris–HCl gels, 4–20%
(456–8093, Bio-Rad). The gels were run for 10 min at
80 V and then for 1 h at 160 V. The gels were blotted onto
PVDF membranes (170–4156, Bio-Rad) using Trans-Blot
Turbo Transfer System (690BR013492, BIO-RAD) and
blocked for 1 h in TBS containing 0.1% Tween (TBST)
and 5% milk. The following antibodies were used for
detecting protein: Anti-SOX10 BC34, (ACI3099, BioCare
Medical), 1:1000 in TBST and 5% BSA, anti-β-catenin
(E-5), (sc-7963, Santa Cruz), 1:100 in TBST and 5% milk,
anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(9101S, cell signaling), 1:1000 in TBST and 5% BSA,
anti-p44/42 MAPK (Erk1/2) (L34F12) (4696S, cell sig-
naling), 1:1000 in TBST and 5% BSA, anti-MITF mono-
clonal antibody (C5), (MA5-14146, Thermo Fisher
SCIENTIFIC), 1:50 in TBST and 5% milk. Anti-GAPDH
Loading Control Monoclonal Antibody (GA1R), (MA5-
15738, Thermo Fisher SCIENTIFIC), 1:1000 in TBST and
5% BSA. Anti-β-Actin, clone AC-74, (A5316, Sigma-
Aldrich), 1:10,000 in TBST and 5% milk. The PVDF
membranes were incubated with antibodies overnight at
4 °C. After three washings with TBST the membranes
were incubated with HRP-coupled secondary antibodies
for 1 h at room temperature (1:2500). The following
antibodies were used: HRP Goat anti-mouse IgG, clone
Poly4053, (405306, Biolegend), HRP anti-rabbit IgG,
clone 6B9G9, (410406, Biolegend). The signal was
detected using Fusion Fx VILBER LOURMAT (12-
200168).
Co-immunoprecipitation
For co-IP experiments, HEK293T/17 cells were transfected
with plasmids pcDNA3.1 (Addgene), flag-β-catenin
(Addgene), and/or HA-SOX10 (Invitrogen), as indicated in
Fig. 2b, using Lipofectamine 2000 (Thermo Fisher Scien-
tific, Illkirch, France) according to the manufacturer’s pro-
tocol. 24 h after transfection, cells were pelleted and lysed
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in IP buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM
EDTA, 1% Triton X100), containing 0.4 µl/ml Benzonase
(E1014-5KU, Sigma), 20 µM MG-132 (S2619, Sell-
eckchem), and PhostSTOP and cOmplete (Roche), as
described above. Protein concentration was then measured
by Pierce BCA assay, as described above. IP was peformed
using Dynabeads® Protein G (Novex, Life Technologies),
according to the manufacturer’s protocol. Briefly, 50 µl of
beads were coupled to 6 µg of anti-HA antibody (H6908,
Sigma) for 10 min at room temperature. After washing,
2000 µg of cell lysate in IP buffer was added and incubated
for 2 h at 4 °C on a rotating wheel. After washing, immu-
noprecipitates were eluted in elution buffer (50 mM glycine
pH 2.8) and NuPAGE® Sample buffer (Thermo Fisher) by
heating at 70 °C for 10 min. Eluates were then loaded for
SDS-PAGE and blotted as described above.
Histochemistry, immunohistochemistry, and
immunofluorescence
Mouse skin samples were fixed in 4% phosphate-buffered
formaldehyde solution (P078.3, Roth) for 2 h and subse-
quently embedded in paraffin (MEDITE PURE Paraffin, 40-
0020-00, MEDITE). Sections of 5 µm thickness were
deparaffinized and rehydrated using the Automatic Staining
System AS-2 (SN: 180.001.1015.119, PATHISTO) and
antigen retrieval was performed in citrate buffer (pH 6.0) for
25 min at 110 °C using Decloaking Chamber (SN: DG12-
220-0134, BIOCARE MEDICAL).
Hematoxylin and eosin staining
Slides were first deparaffinized 10 min for two times in
Histoclear (D1620333, Chemie Brunschwig), then rehy-
drated for 1 min each in 100, 96, 80, 70% EtOH (179-
VL03K-/1, Thommen Furler AG) and ddH2O following
7 min in filtered hematoxylin, three times 10 s in ddH2O,
30 s in Scott Water (8 mM MgSO4 × 7H2O (M2643-500G,
Sigma-Aldrich), 24 mM NaHCO3 (S5761, Sigma-Aldrich)
and 1.5 min in Eosin (0.2%, 41-6660-00, Medite) contain-
ing three drops of CH3COOH. Subsequently slides were
placed two times 10 s each in 50, 70, 80, 95, and 100%
EtOH and finally two times 10 min in Xylol (253-VL03K,
Thommen Furler AG). Then they were mounted using Eukit
Quick hardening mounting medium (03989, Fluka).
Immunohistochemistry
After antigen retrieval, sections were incubated with per-
meabilization buffer (TBS and 0.5% Triton X-100, 93426,
Sigma) for 10 min and washed three times with PBS.
Blocking and antibody incubation were performed as
described in the manufacturer’s protocol (Vectastain ABC
Kit, PK-4000, Vector Laboratories). Signal detection was
performed using the DAB Substrate Kit (ab64238, Abcam)
according to the manufacturer’s protocol.
Immunofluorescence
Sections were incubated with permeabilization buffer (TBS and
0.5% Triton X-100, 93426, Sigma) for 10min, washed three
times with PBS and subsequently incubated in blocking buffer
(PBS, 5% horse serum, and 0.1% Triton X-100) for 45min.
The slides were incubated overnight at 4 °C with the following
primary antibodies: anti-SOX10 (D5V9L), (89356, Cell Sig-
naling), 1:100 in PBS, phospho-ERK1/ERK2 (Thr185,
Tyr187), (700012, 15H10L7), Thermofischer Scientific 1:100
in PBS, purified mouse anti-β-catenin (6110154, BD Trans-
duction Laboratories), 1:200 in PBS, pan Melanoma-Cocktail 2
(MART-1 and Tyrosinase), (CM 178A, BIOCARE MEDI-
CAL), 1:150 in PBS, Ki67: (15580, Abcam) 1:200 in PBS.
After washing three times for 10min, the following secondary
antibodies were applied: 1:250 in PBS for 1 h: Alexa Fluor 647
AffiniPure Donkey Anti-Mouse IgG (H+L), (715-605-151,
Jackson ImmunoResearch LABORATORIES, INC.) CyTM3
AffiniPure Goat Anti-Rabbit IgG (H+L), (111-165-003,
Jackson ImmunoResearch, LABORATORIES, INC.) After
three washing steps in PBS, melanoma cultures were optionally
incubated with Phalloidin control DyLight488 (21833, Invi-
trogen) 1:250 for 20min at room temperature. After three
washing steps, the nuclei were stained and mounted with
DAKO Fluorescent Mounting Medium (S3023, DAKO) and
Hoechst 33342 Tri-Hydrochloride, Trihydrated (H1399,
Molecular probes by life technologies), 1:1000 for 7 min.
The images were captured with Leica DMI6000 B or Leica
SP8 inverse confocal microscope and analyzed using the
LAS AF or Leica LAS X software. Melanoma patient
biopsies were analyzed before and after clinical treatment
with immunohistochemistry. Stainings were conducted as
described above. TMA paraffin sections used in this study
were obtained from the Institute of Pathology and Molecular
Pathology, University Hospital Zurich.
Immunocytochemistry assay
5000 cells were plated into μ-Slide 8 well ibiTreat (80826,
ibidi). After treatment, the medium was removed and the cells
were fixed using 4% PFA for 10min. After three washing
steps, cells were permeabilized for 5min. The staining pro-
cedure was carried out as described for immunofluorescence.
Animal studies
All animal experiments were performed in accordance with
Swiss law and have been approved by the veterinary
authorities of Zurich.
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Xenografts
1 × 106 cells (M111031) were injected subcutaneously in
both flanks of immunocompromised mice (CanN.Cg-
Foxn1<nu>/Crl (BALB/c-nude), Charles River). When first
signs of tumors were appearing, mice were injected i.p. with
30 mg/kg of CHIR99021 (S2924, Selleckchem), diluted in
captisol (RC-0C7-020, captisol) or captisol alone (15%)
until the tumor reached the size of 1 cm3.
Melanoma mouse model experiments
Mice from the Tyr::NrasQ61K Ink4a−/− model were injected i.
p. for 14 days in a row with CHIR99021 (30mg/kg) followed
by weekly injections. Another group of mice served as control
and was injected with captisol (15%) at the same intervals as
the treatment group. The mice were euthanized when they
reached one of the termination criteria, and skin and organs
were embedded in paraffin for immunohistochemistry analy-
sis. Another group of the Tyr::NrasQ61K Ink4a−/− mice was
injected i.p. with CHIR99021 (30mg/kg) and euthanized 24
or 72 h after injection. Skin and organs were analyzed by
immunohistochemistry. Mice from BrafV600E Pten−/− Tyr::
CreERT2 model (6–10-week old) were shaved on the back
skin and 4-hydroxytamoxifen in DMSO was applied topically
on 3 consecutive days (25 mg/ml). 1 week after the first
application, mice were treated i.p. daily with CHIR99021
(30mg/kg) for 2 consecutive weeks, followed by weekly
treatment until termination criteria were reached. Skin and
organs were dissected and embedded in paraffin for immu-
nohistochemistry analysis.
CovalX experiment
nLc Orbitrap mass spectrometry to identify SOX10-
interacting proteins
To identify novel SOX10-interacting proteins, a M010817
WCE was analyzed by nLc Orbitrap MS at CovalX (Cov-
alX AG, Zürich, Switzerland). M010817 were lysed in NE
buffer (50 mM Tris pH 7.5, 150 mM KCl, 0.2 mM EDTA,
5 mMMgCl2, 20% Glycerol, 0.5 mM DTT) and then sent to
CovalX for further analysis, along with purified SOX10
protein in a buffer of 25 mM Tris pH 7.3, 100 mM glycine,
10% glycerol, obtained from Creative Biomart (Creative
Biomart Inc, Shirley, NY, USA). Procedure at CovalX were
as follows:
Dialysis
In a first step, the protein extract and SOX10 were sub-
jected to dialysis. 50 μL of WCE, and 50 μL of SOX10
were pipetted in the dialysis device (Slide-A-Lyzer™,
Thermofisher), and dialyzed against 1 ml of PBS, at 4 °C.
After 2 h of incubation, the buffer was changed with 1 ml
of fresh PBS solution for an additional overnight incuba-
tion at 4 °C.
Mixing samples and cross-link experiments
Three different ratios of WCE/SOX10 were prepared for the
interaction study: 1/1, 1/5, and 1/10. Mixtures prepared
were submitted to crosslinking using 0.5 μl of DSS d0/d12
(2 mg/ml, N,N-Dimethylformamide) for the ratio 1/1,
2.4 μL of DSS d0/d12 for the ratio 1/5 and and 4.8 μL of
DSS d0/d12 for the ratio 1/10. The cross-link samples were
incubated for 3 h at room temperature. After incubation, 2 μl
of a solution of ammonium bicarbonate (500 mM) was
added to the solutions in order to stop the cross-linking
reactions. After 1 h of incubation time, the solution was
evaporated to dryness and suspended in 20 μL of 1X
bromophenol blue.
Trypsin proteolysis
20 μL of each solution was separated by SDS-PAGE and
analyzed by Coomassie blue staining. The protein band was
cut, and proteins reduced with dithiothreitol, alkylated with
iodoacetamide, and finally in-gel digested with trypsin
(overnight, 37 °C). Peptides were extracted from the gel,
evaporated to dryness, and suspended in H2O/formic acid
0.1% to a final concentration of 0.1 μg/μL for ratio 1/5 and
1/10 and 0.05 μg/μl for ratio 1:1. 10 μL of each solution was
injected into the Orbitrap for nLC MS analysis with one
injection for Sequest HT search engine and another injection
for Xquest search engine.
Instrumentation
Measurements were performed using an LTQ orbitrap mass
spectrometer (ThermoFisher) coupled with a nano LC
chromatography (Ultimate 3000, Dionex), equipped with
C18 column (75 μm ID × 15 cm nanoViper C18, 3 μm,
100 Å – Acclaim® PepMap100).
Statistics
Data are presented as the mean ± s.d. of independent
experiments, unless otherwise specified. Statistical analyses
were performed with GraphPad Prism 7.0 (GraphPad
Software) using 2-way ANOVA for multigroup compar-
isons or two-tailed Student’s t test for 2-group comparison,
unless otherwise specified in the figure legends. For survival
analysis a Log-Rank (Mantel–Cox) test was performed to
determine statistical significance. A P value of <0.05 was
considered to be significant.
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